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Epsilon toxin (ET), produced by Clostridium perfringens types B and D, ranks among the
four most potent poisonous substances known so far. ET-intoxication is responsible for
enterotoxaemia in animals, mainly sheep and goats. This disease comprises several
manifestations indicating the attack of the nervous system. This review aims to summarize
the effects of ET on central nervous system. ET binds to endothelial cells of brain capillary
vessels before passing through the blood–brain barrier. Therefore, it induces perivascular
oedema and accumulates into brain. ET binding to different brain structures and to
different component in the brain indicates regional susceptibility to the toxin. Histological
examination has revealed nerve tissue and cellular lesions, which may be directly or
indirectly caused by ET. The naturally occurring disease caused by ET-intoxication can be
reproduced experimentally in rodents. In mice and rats, ET recognizes receptor at the
surface of different neural cell types, including certain neurons (e.g. the granule cells in
cerebellum) as well as oligodendrocytes, which are the glial cells responsible for the axons
myelination. Moreover, ET induces release of glutamate and other transmitters, leading to
ﬁring of neural network. The precise mode of action of ET on neural cells remains to be
determined.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
The bacterial genus Clostridium comprises Gram-
positive anaerobic bacteria, which are present in all kinds
of environments. About 13 clostridia species are major
pathogens exerting their deleterious actions through a
number of toxins, which include the most toxic substances
known so far. Clostridial diseases are not rare in humans
(e.g. antibiotic associated pseudomembranous colitis
caused by Clostridium difﬁcile, intoxications due to foods Cellulaires et Intégratives (I
oulain).
ier Ltd. Open access under CC Bcontamination by Clostridium perfringens, gangrene and
tetanus due to colonization of a wound by C. perfringens or
Clostridium tetani, respectively). Also, they cause consider-
able loss in domestic and wild animals.
Epsilon toxin (ET) produced by C. perfringens types B and
D is one of the most potent clostridial toxins. Very high
lethality of ET (w400,000 mouse LD100/mg protein, i.p.)
ranks it among the four most potent poisonous substances
known so far (reviewed by Gill, 1982). Infection by ET-
producing bacteria occurs via food, water, animal litter orNCI) – CNRS, UPR 3212, 5 Rue Blaise Pascal, 67084 Strasbourg, France. Tel.:
Y license.
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in sheep, goat and cattle. Unfortunately, high stability of ET,
together with the possibility to express it as recombinant
protein into Escherichia coli as well as the lack of relevant
therapeutics, led to the recognition of ET as a potential
biological weapon (Anderson and Bokor, 2012; Greenﬁeld
et al., 2002).
Overall, information on the way(s) by which ET kills the
infected hosts remains scarce. In animals, enterotoxaemia
develops per acutely in most cases, leading to sudden death
without any prior signs of disease. Over-proliferation of C.
perfringens in intestines produces large amounts of ET,
which increases the permeability of the intestinal mucosal
barrier and therefore enters into the bloodstream. Then, ET
diffuses through all organs and accumulates preferentially
into the brain and kidneys (Nagahama and Sakurai, 1991).
ET induces elevation of blood pressure (Buxton et al., 1978;
Nagahama et al., 1993; Sakurai et al., 1983) associated with
an increase in the permeability of the cerebral blood vessels
(Gardner, 1973c; Morgan et al., 1975). However, the ques-
tion whether the major neurological disorders observed in
ET-intoxicated animals result from neural tissue damage
ensuing brain oedema (Barker et al., 1993; Buxton and
Morgan, 1976; Finnie, 2003; Finnie et al., 1999; Uzal and
Kelly, 1997; Uzal et al., 1997) or direct attack of neural
cells constituting brain tissue remains matter of debate.
This review aims to summarize ETeffects on the nervous
system (mainly the central nervous system) and focuses on
the causal linkage between symptoms or manifestations
expressed by intoxicated animals as well as structures
affected, and the potential direct effect of ET on neural cells.
2. C. perfringens and Epsilon toxin
C. perfringens (also termed Clostridium welchii) is a
Gram-positive, anaerobic and spore-forming bacillus. C.
perfringens is a ubiquitous environmental bacterium that
can be found as normal microﬂora component of soil, dust
and sediments. As many other Clostridia, it grows in ca-
davers and litter. Spores are ingested and can reach in-
testines of various vertebrates (McClane and Chakrabarti,
2004). Overall, C. perfringens is considered as a normal
inhabitant of the gastro intestinal tract. Typically, pertur-
bation of microbial balance in the gut (for instance by a
rapid change in diet) induces overgrowth of C. perfringens
leading to production of high level of toxins. Proliferation of
types B and D in gut causes enterotoxaemia in sheep and
goat and more rarely in cattle (Uzal et al., 2002; McClane
and Chakrabarti, 2004). The bacterium has also been
found in pig (Bergeland, 1972; Bergeland et al., 1966; Cho
et al., 1991) and smaller renting animals, such as rabbit
and chicken (Heikinheimo and Korkeala, 2005; Sting,
2009). ET-producing strains of C. perfringens have been
isolated from human intestine (Gleeson-White and Bullen,
1955; Kohn and Warrack, 1955) and upon the occasion of a
case of gas-gangrene (Morinaga et al., 1965). However, it
remains unclear whether the strains isolated had a role in
the disease observed in man. 17 different toxins including
alpha, beta, iota and epsilon toxins are produced by various
strains of C. perfringens. According to produced-toxins, C.
perfringens have been divided into ﬁve main groups, from Athrough E (Finegold, 1977; Fisher et al., 2006; Niilo, 1980).
Only two groups of C. perfringens (types B and D) produce
ET. C. perfringens type B produces ET together with alpha-
and beta-toxins whereas type D produces ET, alpha-toxin
and perfringolysin-O (reviewed by Alouf and Popoff,
2006; McClane et al., 2006; Uzal and Songer, 2008).
ET is a single-chain protein synthesized as a protoxin of
32–33 kDa (McDonel, 1980). Removal of the 11 N-terminal
(or the 13 N-terminal) and of the 29 C-terminal residues
amino-acids by proteases (notably the a-chymotrypsin,
trypsin and l-protease) converts the inactive protoxin
(proET) into a fully active form (i.e. the toxin, ET 28.6 kDa),
with a lethal dose (LD) of about 70 ng kg1 in mice (i.e.
400,000 mouse-LD per mg protein) (Minami et al., 1997;
reviewed by Popoff, 2011a). Proteases involved in conver-
sion of proET into ET are synthesized by C. perfringens
(Minami et al., 1997) as well as by the host (Bhown and
Habeerb, 1977; Worthington and Mülders, 1977). The 3D
structure of ET has been resolved and presents similarities
with the pore-forming toxin aerolysin produced by Aero-
monas hydrophila species (Cole et al., 2004; Gurcel et al.,
2006; Parker et al., 1994). For further details concerning
ET mode of action see x6 and recent reviews written by
Popoff (2011a) and by Bokori-Brown et al. (2011).
3. Symptoms manifestations during naturally
occurring disease or after administration of ET
Proliferation of C. perfringens type D in the intestinal
tract and ensuing production of toxins causes enteric dis-
ease termed enterotoxaemia in sheep and goats, whereas C.
perfringens type B is associated with dysentery (sheep) and
haemorrhagic enteritis (goats) and signs of enterotoxaemia
(reviewed by McClane et al., 2006; Uzal and Songer, 2008).
Enterotoxaemia caused by C. perfringens type D in sheep is a
worldwide problem. The disease is most commonly
observed in lambs (Barker et al., 1993; Songer, 1996),
frequent in goats (Blackwell and Butler, 1992; Blackwell
et al., 1991; Uzal and Kelly, 1996, 1997; Uzal et al., 1994)
and adult sheep and calves (Buxton et al., 1981; Munday
et al., 1973) but less frequent in adult cattle (Radostits
et al., 2000), and has been reported in deers, domesti-
cated camels, horses (Stubbing, 1990). Recently, a suspi-
cious case has even been reported in a tiger (Zeira et al.,
2012).
Naturally occurring enterotoxaemia is commonly
depicted according to 3 grades of manifestations (per-
acute, acute and sub-acute or chronic); the severity of the
disease being correlated to the amount of ET produced by
C. perfringens. In per-acute form, sudden death of animals
occurs without premonitory signs. In sheep, the acute
form is characterized by a combination of severe neuro-
logical (as convulsions) and respiratory troubles; diar-
rhoea is infrequent. The recovery from the acute form of
the disease is rare. In sheep, systemic lesions are observed
(such as petechiae, brain and lung oedemas) with minor
changes in the intestine (Fernandez-Miyakawa et al.,
2003; Uzal and Songer, 2008). At variance, the chronic
form is rarely observed in sheep suggesting very mild
manifestations while the brain tissue displays signs of
focal symmetric encephalomalacia (see below, x4) (Uzal
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in goats, the acute form provoked by C. perfringens
intoxication affects mostly young animals while chronic
form of the disease is more frequent in adults. In goats,
diarrhoea is the most frequent manifestation (Uzal and
Songer, 2008; Oliveira et al., 2010).
Symptoms and manifestations observed either in the
naturally occurring disease or after experimental intoxi-
cation (i.e. either by injecting C. perfringens in the gastro-
intestinal tract or ET in the duodenum, intraperitoneally
or intravenously) can be sorted into groups according to
the altered-physiological system: intestinal, renal, pul-
monary and nervous systems. These numerous manifes-
tations are summarized in Table 1 (in which are quoted
the corresponding references). A ﬁfth category of mani-
festations regroups a number of heterogeneous behav-
ioural alterations, including reluctance to suck, haphazard
roaming, anorexia and weight loss (Table 1). The multiple
manifestations observed in enterotoxaemia caused by C.
perfringens type D (which produces high amounts of ET)
reveal a prominent alteration of the nervous system. For
instance, opisthotonus or hypotonus, which are extra-
pyramidal motor symptoms, indicates functional impair-
ment of central structures involved in the control of body
postures and movements, such as putamen, thalamus,
caudate nucleus and globus pallidus, or from alteration ofTable 1
Summary of literature-reported symptoms and manifestations occurring after in
System affected Symptoms and manifestations Species
Intestinal system Haemorrhagic diarrhoea Calve, Lamb,
Goat, Sheep
Abdominal discomfort Goat
Tenesmus Calve
Pulmonary system Laboured breathing Calve, Goat
Dyspnoea Sheep
Renal system Glycosuria Sheep
Central Nervous
system
Convulsion Calve, Goat,
Mouse, Sheep
Opisthotonus Sheep, Goat,
Calve, Mouse
Incoordination Mouse, Rat, Sheep
Tremor Pleurothonus Mouse, Rat, Sheep
Coma Calve, Sheep
Nystagmus Sheep
Strabismus Sheep
Ptyalism Calve, Sheep
Bruxism Sheep
Paralysis Sheep, Goat,
Calve, Rat
Hypotonus Sheep, Rat
Rigidity of limbs Goat, Lamb, Rat
Retraction of the head Sheep
Allodynia Calve
Behavioural
alteration
Bleating Sheep
Anorexia Goat
Weight loss Goat
Depression Lamb, Goat, Mouse
Staggering Calves
Haphazard roaming Sheepthe tracts connecting these structures. Manifestations that
belong to the ﬁfth group (Table 1) indicate some decline of
cognitive function, either due to direct alteration of cen-
tral nervous physiology or to pain. Diarrhoea and
tenesmus are clinical signs of an ET action on the intestinal
system, which may be, in part, a consequence of an effect
of the toxin on the enteric nervous system. Indeed, there
are increasing evidence indicating that some enterotoxins
mediate diarrhoea not only by acting directly upon
enterocytes, but also by interfering with the enteric ner-
vous system (Berkes et al., 2003; Farthing, 2004, 2000;
Popoff and Poulain, 2010). Elevated blood pressure
(Sakurai et al., 1983) can be caused by renal damage and/
or overstimulation of the ortho-sympathetic part of
autonomic nervous system as suggested by observations
of an increase in circulating monoamines levels (Buxton,
1978b; Nagahama and Sakurai, 1993; Worthington et al.,
1979).
Several bodies of evidence support the notion that ET is
the main etiological cause for the various manifestations of
enterotoxaemia. Indeed, in vivo intoxication experiments
performed in sheep, goats, lambs (Buxton and Morgan,
1976; Griner, 1961; Uzal and Kelly, 1997) and cattle (Uzal
et al., 2002) leads to similar clinical signs as observed
during the naturally occurring disease (see Table 1). Thus
administration of ET can recapitulate the natural disease.toxication with Clostridium perfringens Epsilon toxin.
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reproduced in rodents by inoculating the bacteria or the
toxin intragastrically (Fernandez-Miyakawa et al., 2007b)
or into the duodenum (Blackwell et al., 1991; Fernandez-
Miyakawa and Uzal, 2003; Uzal et al., 2002), as well as by
administrating ET intravenously (Uzal et al., 2002) or
intraperitoneally (Fernandez-Miyakawa et al., 2007a;
Finnie, 1984a, 1984b; Finnie et al., 1999; Miyamoto et al.,
2000, 1998). Studies in mice clearly show that the
lethality of different C. perfringens strains is directly corre-
lated with their ability to produce high levels of ET
(Fernandez-Miyakawa et al., 2007a, 2007b). This further
supports the notion that ET is the causative virulence factor
of all symptoms and lesions caused by C. perfringens type D
(Sayeed et al., 2005).
C. perfringens type B produces ET together with variable
amounts of alpha and beta toxins, and causes animal ill-
nesses characterized by sudden death or acute neurological
signs, with or without intestinal damage (reviewed by
Finnie, 2004; Uzal and Songer, 2008; Uzal et al., 2004).
Since the enterotoxaemia due to C. perfringens types B and
C share similar neurological signs while type B produces
both beta-toxin and ET whereas the type C synthesizes only
the beta-toxin (reviewed by McClane et al., 2006), the
question of whether other toxin(s) produced together with
ET may explain some of the neurological aspects of the
disease was raised. Experiments performed in mice
demonstrated that none of the C. perfringens type B or D
toxins, except ET, is indispensable for inducing illness.
However, the other toxins seem to play a synergistic/
potentiating role together with ET (for the contribution of
beta-toxin to the pathogenesis of C. perfringens type B, see
Fernandez-Miyakawa et al., 2007a; for the potentiating role
of alpha-toxin and perfringolysin-O, see Fernandez-
Miyakawa et al., 2008). Sialidases from C. perfringens type
D may play a role (Li et al., 2011), see also below. However,
the mechanism underlying the potentiating role of the
other toxins of factors is still unclear. Possibly, they may
favour dissemination of ET by increasing vascular perme-
ability (Fernandez-Miyakawa et al., 2008, 2007a).
To summarize, administration of ET mimics the natu-
rally occurring disease produced by C. perfringens types B or
D. The observed clinical manifestations (Table 1) indicate
prominent alterations in the central nervous system func-
tions. Sudden death may result from severe brain damage;
however, it can be caused by blood pressure elevation or
heart failure. In the next paragraphs we summarize how ET
can pass from the intestine to the brain and generates
damage in the central nervous system.
4. From intestine to brain tissue
Since ET is produced into the gut lumen, it should ﬁrst
cross the intestinal barrier before being disseminated in the
whole organism. Many studies have addressed this step
(for reviews see Finnie, 2004; Popoff, 2011a). ET binds to
mucosal epithelium of small intestine (Goldstein et al.,
2009). ET induces decrease in the trans-epithelial resis-
tance in a time- and dose-dependent manner (Fernandez-
Miyakawa et al., 2003; Goldstein et al., 2009). Since no
histological and ultrastructural changes in the intestinalepithelium have been observed (except paravascular
oedema and presence of apoptotic cells in the lamina pro-
pia, Goldstein et al., 2009) ET may cross the intestinal
barrier by passing through the paracellular pathway,
possibly by opening the mucosa tight junctions (reviewed
by Popoff, 2011a, 2011b). However, despite ET decreases
trans-epithelial resistance in cultured conﬂuent renal
epithelial cells, as the MDCK (Madin–Darby Canine Kidney)
cells (Petit et al., 2003) or mpkCCDc14 immortalized mouse
kidney cells (Chassin et al., 2007), no alteration of the tight
junctions is detected between the renal cells. Therefore,
severing of tight junctions is not a general effect of ET on
epithelia. The ET-induced alterations of intestinal barrier
permit bidirectional passage of proteins, including ET, be-
tween the intestinal lumen and the plasma compartment,
as assessed using Horse Radish Peroxidase or Evans blue
bound to plasma proteins (Goldstein et al., 2009). Thus, by
altering the intestinal permeability, ET facilitates its own
passage in the circulatory ﬂuids (Fernandez-Miyakawa and
Uzal, 2003; Losada-Eaton et al., 2008). To summarize,
whereas the mechanisms in which enterotoxin from C.
perfringens opens tight junctions is well known (reviewed
by Berkes et al., 2003; McClane et al., 2006; Popoff, 2011b),
the way in which ET toxin modulates the tight junctions
remains unclear.
Following haematogenous dissemination, ET reaches
central nervous system. The second step is the passage of
ET through the blood–brain barrier. The latter consists of
endothelial cells stitched together by tight junctions that
restrict the passage of large molecules from blood to brain.
After intraperitoneal ET injection in mice, many capillaries
are reduced to a thin electron dense band, indicating major
changes in endothelial cells (Finnie, 1984b). Following
intravenous injection of protoxin or toxin tagged with
Green-Fluorescent-Protein (proET-GFP or ET-GFP) in mice,
both proET-GFP and ET-GFP can be detected bound onto the
luminal surface of the vascular endothelium (Soler-Jover
et al., 2007). Studies performed using EBA (endothelial
barrier antigen) to assess the integrity of blood–brain bar-
rier in rats, have revealed severe alteration of the barrier
following intraperitoneal administration of proET (Zhu
et al., 2001). However, consistent with lack of biological
activity of proET, others have found that proET remains
bound onto the luminal surface of the vascular endothe-
lium, whereas ET-GFP induces blood–brain barrier disor-
ganization and passes through (Soler-Jover et al., 2007).
Therefore, the observation that endogenous albumin
extravasation occurs after proET application (Zhu et al.,
2001) is likely due to the conversion of proET into fully
active ET by the plasma and tissue proteases. With this
respect, note that a major difference between the above
mentioned studies resides in the delay between proET in-
jection and animal sacriﬁce: 1 h to 14 days post-injection
(Zhu et al., 2001) vs. 7 min post-injection (Soler-Jover
et al., 2007). This delay may allow signiﬁcant activation of
proET into ET by the body proteases. In mouse, rat or lamb
brains, severing of the blood–brain barrier leads to passage
of proteins, like serum albumin (endogenous, coupled to
Alexa-677, or 125I human serum albumin) as well as Horse
Radish Peroxidase or 125I-polyvinyl-pyrrolidone (Buxton,
1976; Finnie et al., 2008, 1999; Griner and Carlson, 1961;
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tissue has been found more diffused than that of albumin,
which remains conﬁned around the damaged vessels
(Soler-Jover et al., 2007). Interestingly, the property of ET to
open the blood–brain barrier has been exploited to allow
delivery of bleomycin, an anti-tumour agent, in rats
(Hirschberg et al., 2009).
5. Tissular and cellular lesions in the central nervous
system
Penetration of ﬂuid into cerebral parenchyma causes
formation of oedema (for references see Table 2), the
spread of which depends on both ET concentration and
the time between ET application and observation. When
high doses of ET cross the blood–brain barrier, the disease
is very severe leading to quick death. As compared to the
observed generalized vasogenic oedema, other brain le-
sions appear tiny. By contrast, when low doses of ET are
applied, fatal issue is strongly delayed, allowing
numerous brain lesions to develop, which are preferen-
tially located in structures such as the basal ganglia, cer-
ebellum, internal capsule, thalamus, and, at a lesser
extent, hippocampus (see Table 2). The cerebellum is a
predilection site for the induction of early central nervous
system damage (Finnie, 1984a, 1984b; Finnie et al., 1999;
reviewed by Finnie, 2004). Overall, the observed lesions
are fully consistent with the neurological manifestationsTable 2
Summary of literature-reported tissue-damage occurring after intoxication with
Damage/effects Species Structures
Vasogenic Oedema Goat, Lamb,
Mouse, Rat,
Sheep,
Basal gangliaa, internal capsule,
thalamus, cerebellum
Coning Mouse, Sheep Cerebellum
Microangiopathy Sheep Brain
Dark haemorrhagic
focic
Lamb, Sheep Basal ganglia, thalamus, cerebellum,
cerebellar whiter matter cores,
cerebral cortex, pons, medulla,
cerebellar peduncles, occipital pole,
cortexb, hypothalamusb
Goat
Perivascular
proteinaceous
oedemac
Lamb, Sheep Basal ganglia, thalamus, cerebellum,
cerebellar whiter matter cores, cortex
hypothalamusb
Goat Internal Capsule, Colliculus superior
Mouse Brain
Calves Cerebellum, internal capsule, thalamu
Degeneration/ Distortion
of white matterc
Sheep Basal ganglia, thalamus, internal caps
midbrain, cerebellar peduncles and
cerebellar white matter cores
Goat Brain
Mouse Cerebellum, cerebral cortex
a The main components of the basal ganglia are the striatum (caudate and puta
nucleus.
b Less frequently.
c These chronic manifestations of ET neurotoxicity are called Focal symmetricobserved during enterotoxaemia (see Table 1). For
instance, opisthotonus results mainly from lesions of the
basal ganglia; seizures may be related to damage in hip-
pocampus as well as thalamus; ataxia may result from
attack of cerebellum or thalamus, notably. These lesions
may result from direct action of ET on neural cells (see
below and x5) or indirectly caused by excessive glutamate
release (see x6).
Brain tissue lesions are characterized by dark peri-
vascular oedema, haemorrhagic foci, degeneration or
distortion of the white matter, and brain necrosis (for ref-
erences see Table 2). Since these alterations are mainly
bilateral and symmetrical, they were collectively termed
Focal Symmetrical Encephalomalacia. It is unclear whether
the symmetry of the lesions is due to higher ET suscepti-
bility of the neural tissue in certain brain bilateral struc-
tures, or due to a regional and bilateral susceptibility of the
brain vasculature for disruption of the blood–brain barrier.
Similar symmetrical lesions have been reported in the case
of naturally occurring disease in different species including
goats, sheep and lambs, and have been reproduced exper-
imentally in sheep, goats, calves, and rodents (rats, mice)
(for references see Table 2). Note that in goats, reports of
histological changes in brain are scarce (Barker et al., 1993;
Songer, 1996), possibly due to less severe symptoms
expressed in this animal species (reviewed by Songer,1996;
Uzal and Songer, 2008; Uzal et al., 2004). Another sign of
suffering brain is the coning of cerebellum (protrusion ofClostridium perfringens Epsilon toxin.
Occurring References
Experimentally Barker et al., 1993; Buxton and Morgan 1976;
Finnie, 2003; Finnie et al., 1999; Uzal and
Kelly, 1997; Uzal et al., 1997
Experimentally Buxton, 1978a, 1978b; Buxton and Morgan,
1976; Fernandez-Miyakawa et al., 2007b;
Pimentel et al., 2010;Uzal, 2004; Uzal and
Kelly, 1998; Uzal and Songer, 2008
Naturally
Experimentally
Uzal et al., 1997
Experimentally Buxton and Morgan, 1976; Buxton et al.,
1978; Hartley, 1956
Uzal et al., 1994
b,
ND Buxton, 1978a, 1978b; Buxton and Morgan
1976; Buxton et al., 1978; Uzal et al., 2004
Experimentally and
Naturally
Uzal and Kelly, 1998, 1997; Uzal et al., 1997,
1994
Experimentally Fernandez-Miyakawa et al., 2007b; Finnie,
1984a, 1984b; Finnie and Hadjuk, 1992;
Morgan et al., 1975
s Experimentally Uzal et al., 2002
ule, Experimentally Buxton and Morgan 1976; Buxton et al.,
1978; Hartley, 1956
Naturally Uzal et al., 1997
Experimentally Finnie, 1984a, 1984b
men nuclei), the globus pallidus, the substantia nigra, and the subthalamic
al Encephalomalacia.
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species (reviewed by Uzal, 2004). This manifestation may
be related to an increase in the intraventricular or blood
pressure (Sakurai et al., 1983).
Altered neurons are found scattered among apparently
normal nerve cells in the cerebral cortex, hippocampus,
thalamus, basal ganglia and cerebellum. Cells damage
observed in neural tissue following exposure to ET (Table 3)
can be sorted into two categories: i) cellular swelling with
microvacuolation, and ii) presence of hyperchromatic cells,
also called dark cells, (possibly being post-mortem histo-
logical neuronal artefacts resulting from brain manipula-
tion, Jortner, 2006), and shrunken cells with nuclear
pyknosis. Tissular localization and severity of cells damage
depend on ET doses, on the delay between ET injection and
animal sacriﬁce (Finnie, 1984a, 1984b; Finnie et al., 1999;
Miyamoto et al., 2000, 1998) as well as on the repetition of
ET injection (Finnie, 1984b; Uzal et al., 2002), but not on the
way of its administration (natural disease, intravenous or
intraperitoneal injection of ET); see Table 3. Some swelling
and pyknotic granule cells have been observed in mouse
cerebellum (Finnie, 1984b) but not (or to a lesser extent) in
rat cerebellum (Finnie et al., 1999; Miyamoto et al., 1998). In
rat, injection of ET at a sub-lethal dose (50 ng/kg) seems to
cause neuronal damage predominantly in the hippocam-
pus (Miyamoto et al., 1998). Overall, this suggests that ET
may have different mode of action or different conse-
quences depending to the cells or the animal species.
6. Neural cells are ET targets
Post-mortem observations of severed neural cells do not
allow discriminating between direct and indirect cellular
actions of ET. On the one hand, cell alteration in brain tissue
may be an indirect consequence of vasogenic oedema:
reduction of parenchyma perfusion leads to hypoxia and
cell necrosis. On the other hand, the bilateral symmetry of
the damage caused by ET (Table 2, and any sign of Focal
Symmetrical Encephalomalacia), notably in the brain stem
(Finnie et al., 1999) suggests a nerve-tissue or neural cells
vulnerability to ET.
Brain tissue is comprised of different types of neural
cells, including many sub-types of neurons, and glial cells
notably astrocytes (velimentous astrocytes, radial glia, etc.)
and oligodendrocytes (which are responsible for myelina-
tion of certain neuronal axons and therefore contribute toTable 3
Summary of literature-reported cell damages occurring after intoxication with C
Cellular damages Species Structures
Cellular swelling Rat Basal gangliaa, cerebellar cortexc
and white matterc
Mouse Cerebellum
Hyperchromatic and
shrunken cellsb
Mouse Cerebellum, hippocampus
Rat Cortex Cerebral, hippocampus,
corpus callosumc, striatumc,
cerebellumc, thalamus
a The main components of the basal ganglia are the striatum (caudate and puta
nucleus.
b Often called dark cells.
c Mild and patchy, only observed with an increasing of ET concentration or ththe formation of the cerebral white matter). In the periph-
eral nervous system, Schwann cells, which are related to
oligodendrocytes, ensure myelination of peripheral axons.
The observed cellular manifestations (binding, cell
damage or death) caused by ET, and the identiﬁcation of cell
types affected by this toxin depend on the actual concen-
tration of ET in the neural tissue. The local concentration of
ET is likely depending, inpart, on thewaybywhich the toxin
is administered. Indeed, during the in vitro studies (i.e.when
neural tissue slices or primary cultures are used) concen-
tration of ET is likely to be homogenous while, during the
in vivo studies (i.e. using gastro-enteric, intraperitoneal or
intravenous injections) tissular concentration of ETdepends
of the limiting steps due to passage of ET through the
different epithelial barriers so that the actual concentration
of ET in neural tissue remains unknown and may be non-
homogenous depending on the damage caused to the
blood–brain barrier.
The possibility that ET binds on speciﬁc subsets of neural
cells has been addressed by analysing ET cell binding, either
usingET-GFP, ET taggedwithAlexa488aswell as 125I-ETorby
the aid of immunolabeling techniques. Overall, ET bindingon
neural tissue isobserved in the samegross structuresas those
displaying tissular lesions following in vivo exposure to ET
(naturally occurring- or experimental disease). For instance,
ET binds to the cerebellum, hippocampus, thalamus, cerebral
white matter and commissures, and basal ganglia (Dorca-
Arévalo et al., 2008; Lonchamp et al., 2010). However, as
discussed below, there is no perfect matching between
cellular binding and the observed cellular damage.
6.1. ET binds to a subset of neurons
Using slices of mouse cerebellum submitted to ET (ET
being applied on acute slices or after ﬁxation of the slices),
examination of the cellular localization of ET immuno-
staining has revealed that the toxin binds to the cell body of
cerebellar granule cells, which are glutamatergic neurons
(Fig. 1A and C). This identiﬁcation is conﬁrmed by the
observation that ET colocalizes with speciﬁc granule cells
markers such as the alpha-6-GABAA receptor subunit or
potassium channel subunit Kv3.1b (Lonchamp et al., 2010).
In the granule cells layer of the cerebellar cortex, ET
colocalizes with MAP-2 (microtubules-associated protein-
2) denoting that ET decorates not only the somata but
also the dendritic trees of granule cells. In primary culture,lostridium perfringens Epsilon toxin.
Occurring References
Experimentally Finnie et al., 1999
Experimentally Finnie, 1984a, 1984b; Gardner, 1973b;
Morgan and Kelly, 1974
Experimentally Finnie, 1984a,1984b; Miyamoto et al., 2000
Experimentally Finnie et al., 1999; Miyamoto et al., 1998;
Zhu et al., 2001
men nuclei), the globus pallidus, the substantia nigra, and the subthalamic
e time after ET administration.
Fig. 1. Identiﬁcation of the cell types labelled by ET. ET (107M)was applied for 5min afterﬁxation (paraformaldehyde 4%) in the different preparationsquoted inA, B, C
andD.ET labellingwas identiﬁedusingan immunoafﬁnitypuriﬁedrabbit anti-ETprimaryantibody (Lonchampetal., 2010). ETbinds tooligodendrocytes (C–D)but not to
astrocytes (A–B). A. Acute cerebellar slices.A1:mergeofET (in red) andspeciﬁc astrocytes-markerGFAP (ingreen) immunoreactivities, andDraq5DNA labelling (inblue).
Note that astrocytes, which are the GFAP positive cells, are not labelled by ET. B2: GFAP immunoﬂuorescence in isolation. Scale bar: 25 mm. GC: granule cells,WMwhite
matter. B. Primary culture of cerebellar cells. B1: ET staining (in green), B2: speciﬁc astrocytes-marker immunoreactivity GFAP (in red). B2: merge of ET and GFAP im-
munoreactivities; Draq5 DNA labelling (blue). Scale bar: 10 mm. C. Acute cerebellar slices. C1: ET staining (in green), C2: merge of ET and speciﬁc Purkinje cells- marker
Calbindin (in red) immunoreactivities. Note the strong ET immunoreactivity in the white matter where myelinated ﬁbres are concentrated. Scale bar: 50 mm. ML:
molecular layer, GC: granule cell layer, WMwhite matter. D. Oligodendrocytes cell lines 158N (a generous gift from Dr M.S. Ghandour). D1: ET staining (in green). D2:
speciﬁc astrocytes-marker CNPase immunoreactivity (in red), B: merge of ET and CNPase immunoreactivities. Scale bar: 20 mm.
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et al., 2010, and Fig. 1B). In a sharp contrast, studies per-
formed by incubating sections of mouse cerebellum with
ET-GFP have not shown signiﬁcant labelling of granule cells
(Dorca-Arévalo et al., 2008). Perhaps the discrepancy be-
tween these studies is related to the use of ET vs. ET-GFP, or
to the timing in the tissue ﬁxation. Indeed, when ET is
applied onto cerebellar slices, intensity of ET labelling in
white mater and oligodendrocytes increases greatly with
incubation time (unpublished data), possibly occluding
signal from granule cells. In the mouse cerebellum, not all
neurons are recognized by ET: Indeed, this toxin is detected
neither onto the GABAergic interneurons like the basket
cells, stellate cells and Golgi cells nor onto the large Pur-
kinje cells (which are GABA-ergic) (Lonchamp et al., 2010).
Therefore, ET is able to bind to a subset of neurons. The
question of whether neurons targeted in other brain re-
gions are glutamatergic remains to be addressed.
Importantly, there is no clear correlation between
manifestation of cellular damage and susceptibility to ET.
Indeed, a possibility to consider is that the cellular and
tissular alterations observed in brain tissue (Tables 2 and 3)
in the context of enterotoxaemia may result in part from
indirect action of ET. As discussed below into details (see
x7), ET induces release of large amounts of glutamate, and
when the homeostasis of this excitatory amino-acid is
positively dis-balanced, glutamate can induce cell death in
many cell types including neurons (like Purkinje cells,
reviewed by Slemmer et al., 2005), and glial cells (astro-
cytes and oligodendrocytes; reviewed by Matute et al.,
2006). Therefore, observations of hyperchromatic Pur-
kinje cells after in vivo exposure of rats to ET (Finnie et al.,
1999), while ET does not bind onto these cells in mice
(Lonchamp et al., 2010), might be re-read as a manifesta-
tion of glutamate-induced excitotoxicity rather than a
direct action of ET on Purkinje cells.
6.2. Does ET bind onto nerve terminals?
Since ET can trigger the release of neurotransmitters
(see Section 7 below), several studies have addressed its
binding onto nerve terminals leading to controversial re-
sults. Indeed, on the one hand 125I-ET has been reported to
bind to rat synaptosomes (Miyata et al., 2002, 2001;
Nagahama and Sakurai, 1992), but on the other hand, ET-
GFP has been found unable to bind to mouse and rat
nerve terminals (Dorca-Arévalo et al., 2008). The discrep-
ancy between the conclusions of these studies is likely
residing in the contamination of the synaptosomal prepa-
rations with resealed myelin debris, which is a common
artefact when preparing synaptosomes. This possibility is
supported by the demonstration that ET-GFP binds to
myelin structures present in mouse brain synaptosomal
preparation (as demonstrated by co-staining of ET with
myelin basic protein; Dorca-Arévalo et al., 2008). The lack
of ET binding onto nerve terminals is also supported by
analysis of ET-immunostaining in cerebellum slices. In this
preparation, ET has not been detected in the cerebellar
molecular layer, which contains the granule cells nerve
terminals making synapse with the Purkinje cells (100,000
synaptic contacts per Purkinje cells) or inhibitoryinterneurons. Also, in the granule cells layer, there is no
colocalization of ET with synaptic vesicles markers like
synaptotagmin or synaptophysin indicating that ET does
not bind to the large glutamatergic nerve terminals of the
mossy-ﬁbres making synapse with the granule cells
(Lonchamp et al., 2010). From the data obtained in cere-
bellum slices, ET binding looks compartmentalized onto
the neurons that respond to the toxin: ET stains primary
dendrites and somata, but not axons or nerve terminals.
This suggests that ET receptor is not ubiquitously expressed
at the neuronal surface. However, such a compartmentali-
zation is loss in primary culture (Lonchamp et al., 2010).
6.3. Binding of ET to oligodendrocytes
The white matter in central nervous system is the
prominent component labelled by ET in several species
(sheep, cattle, mouse, and human) (Dorca-Arévalo et al.,
2008). This is consistent with post-mortem alterations of
white-matter observed in intoxicated animals (Table 2).
Whatever is the manner it is administered (ET-GFP intra-
venous injection or ET application onto acute brain slices),
ET co-localizes with myelin markers as MBP (myelin basic
protein) or CNPase (20,30-Cyclic Nucleotide 30-Phosphodi-
esterase) (Dorca-Arévalo et al., 2008; Lonchamp et al., 2010;
Soler-Jover et al., 2007). In addition, ET binds to myelinated
axons in peripheral nerves (Dorca-Arévalo et al., 2008).
Taken together, these data indicate that ET binds to oligo-
dendrocytes,which are the glial cells formingmyelin sheath
around the axons. The identiﬁcation of oligodendrocytes as
ET targets is supported byour preliminary observations that
ET binds to cell line Oligo-158N derived from rat oligoden-
drocytes, as well as to rat oligodendrocytes in primary cul-
ture (Fig. 1D, Wioland et al., 2012).
6.4. Binding of ET to astrocytes
The question of whether ET can target members of the
astrocyte lineage (which are glial cells, too) has been
addressed. In cerebellar cortex, large radial astrocytes
termed Bergmann glia are present in the molecular layer.
However, no ET binding has been observed in this layer. In
the granule cells layer, ET staining does not colocalize with
GFAP (Glial Fibrillary Acidic Protein) that is a speciﬁc
marker for astrocytes. Similar results have been found
using either acute or ﬁxed cerebellar slices, or primary
cultures containing both granule cells and astrocytes
(Fig. 1A and B; Lonchamp et al., 2010). By contrast, ET-GFP
injected intraperitoneally has been reported to bind to
astrocyte perivascular end-feet (Soler-Jover et al., 2007).
The origin of the difference mentioned above remains un-
clear. Perhaps ET-GFP binds to capillary endothelial cells
that are tightly apposed to the astrocyte perivascular end-
feet, leading to the appearance that ET was bound to the
astrocytes. Also, one cannot exclude the possibility that ET
may target a speciﬁc subclass of astrocytes.
7. The mechanisms by which ET acts on neural cells
ET is a member of a large group of cytolysins, the cyto-
toxicity of which is believed to be related to their ability to
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transmembrane pores (for recent general review, see
Dunstone and Tweten, 2012). Few reports address the
mechanisms by which ET acts on individual neural cells.
However, insights gain from experiments performed using
brain or neural preparations suggest commonalitieswith the
ET mechanisms established using renal cells. Therefore, in
the following paragraphs we will discuss ET mechanisms in
neural and renal cells. We will address separately the steps
of binding and oligomerization, and the pore formed by ET.
Then we will discuss the role played by the cholesterol in
these several steps. Finally, we will brieﬂy comment several
data that are not fully consistent with the notion that the
cytotoxicity is exclusively related to the pore-forming action
of ET.
7.1. Binding to its receptor
Immuno-labelling studies have shown that ET binds to a
subset of neural cells including certain neurons, and oli-
godendrocytes (see previous Section 5). Studies performed
using 125I-ET and 125I-proET have revealed that both pep-
tides share the same receptor. Their binding onto rat brain
homogenates and synaptosomal membrane is saturable,
with a single dissociation constant in the nanomolar range
(Nagahama and Sakurai, 1992). Very similar ﬁndings have
been made using mpkCCDc14 mouse kidney cells (Chassin
et al., 2007) or MDCK cells (with a dissociation constant
in the nanomolar range, too; Dorca-Arévalo et al., 2012).
Taken together these observations suggest that ET binds to
single receptor type, possibly expressed by both neural and
renal cells (but see below). However, since ET can form
pores (see x6.3) into artiﬁcial membrane bilayers
(Nagahama et al., 2006; Petit et al., 2001) that are devoid of
speciﬁc receptor for ET, ET binding to its receptor is not
absolutely indispensable for pore formation.
ET binding to isolated membranes from rat brain
(Nagahama and Sakurai, 1992) or to white matter mice
cerebellum slices (Dorca-Arévalo et al., 2008) is inhibited
by treatment with pronase. On the contrary, ET binding to
target cells is not or weakly affected by phospholipase C,
glycosidases, or neuraminidase (Dorca-Arévalo et al., 2008;
Nagahama and Sakurai, 1992). Therefore, ET receptor on
neural cells (including certain neurons and oligodendro-
cytes) is likely to be a protein or a glycoprotein. This cor-
roborates prior deduction on the protein nature of ET
receptor on renal cells (Petit et al., 1997). Differences in
molecular weight of ET-binding proteins (i.e. receptor
candidates) in renal and brain cells suggest that distinct
proteins may be implicated into ET binding (reviewed by
Popoff, 2011a). Hepatitis-A virus cellular receptor 1
(HAVCR1, also termed KIM-1 for Kidney injury molecule-1)
has been shown contributing to ET binding (Ivie and
McClain, 2012; Ivie et al., 2011). However no role is
known for this protein in the nervous system as yet.
Contribution of ganglioside moiety to ET binding onto
the cell membrane is supported by early observation that
treatment with neuraminidase decreases ET-binding on rat
brain homogenates or synaptosomal membranes, leading
to the proposal that ET-receptor might be a sialoglyprotein
(Nagahama and Sakurai,1992) or an O-glycoprotein (Dorca-Arévalo et al., 2008). Treatment by sialidase can modify the
ganglioside content in membrane and has been shown
modulating ET binding on MDCK cells (Shimamoto et al.,
2005). Inhibition of sphingolipids and glycosphingolipids
synthesis increases susceptibility of MDCK cells to ET,
whilst inhibition of sphingomyelin decreases it. The pres-
ence of GM1 decreases the effects of ET, while GM3 does
the contrary (Shimamoto et al., 2005). Above observations
are compatible with ET binding to a double receptor
comprised of a protein and ganglioside(s), as it has been
described for clostridial neurotoxins (reviewed by Binz and
Rummel, 2009).
7.2. Oligomerization
After binding to its receptor, ET but not proET oligo-
merizes (reviewed by Bokori-Brown et al., 2011; Popoff,
2011a) to form a large membrane complex of 155 kDa–
200 kDa in rat synaptosomes (Miyata et al., 2002, 2001),
mouse brain homogenates (Nagahama et al., 1998), lipo-
somes (Nagahama et al., 2006), as well as in MDCK cells
(Miyata et al., 2002; Petit et al., 1997) or in mpkCCDc14
mouse renal cells (Chassin et al., 2007). By their size, the
observed complexes correspond to ET heptamers. Studies
made using artiﬁcial membranes revealed formation of
oligomers of intermediate sizes (Nagahama et al., 2006)
indicating that heptamers are formed by progressive
addition of monomer to oligomer of smaller size. The
question of whether ET oligomerizes before membrane
insertion or heptamerization process occurs with ET-
monomers already incorporated to membrane remains
matter of debate. When studies are performed using cell
membranes, no oligomer of intermediate sizes is observed
into membrane (Chassin et al., 2007; Miyata et al., 2002)
suggesting either that ET monomers inserted into mem-
brane assemble very quickly to form heptamers, or that
heptamers are inserted into membrane as a whole.
Importantly, ET oligomers formed at 4 C in MDCK cells
display greater sensitivity to pronase treatment than those
formed at 37 C: this supports the notion that ET assembles
as a pre-pore complex onto the membrane surface before
heptamers insertion into the bilayer in a temperature-
sensitive manner (Robertson et al., 2011). Thus, ET looks
behaving similar as many other pore-forming toxins
(Dunstone and Tweten, 2012). Since a single class of satu-
rable ET binding sites has been detected on synaptosomes
and renal cells (Dorca-Arévalo et al., 2012; Nagahama and
Sakurai, 1992), the toxin oligomer incorporated to plasma
membrane is likely to remain attached to ET receptor;
otherwise oligomers inserted into membrane should have
been detected as an additional non-saturable binding
component.
7.3. The pore formed by ET
Direct information on ET pores is scarce. The pore
formation has been deduced from observation that pro-
pidium iodide can cross plasma membrane in MDCK cells
under condition enabling ET to form oligomers (Lewis
et al., 2010; Petit et al., 2003, 2001). Moreover ET in-
duces an early efﬂux of Kþ ions and inﬂux of Naþ and Cl
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tion of ET-pore in plasma membrane. In artiﬁcial bilayers,
ET pores have been recorded; they are characterized by a
large conductance of 480–550 pS and low selectivity for
ions (Cl > Kþ) (Nestorovich et al., 2010; Petit et al.,
2001). ET pore is highly asymmetric, with a cut-off size
of polymers entering the pore from the cis side about
500 Da, whereas the one entering from the trans side is
about 2300 Da (Nestorovich et al., 2010). Altogether,
these data indicate that when inserted into membrane,
ET heptamers forms general diffusion pores allowing
passage of rather large compounds (about 1 kDa).
Consistent with the formation of ET pores in target cells
membrane, a dramatic decrease in individual cell trans-
membrane resistance has been detected using single cell
recording of renal collecting duct mpkCCDcl4 cells
(Chassin et al., 2007) and of cerebellar granule cells
(Lonchamp et al., 2010). Appearance of abrupt steps in
trans-membrane currents recorded in granule cells using
the whole cell conﬁguration (Lonchamp et al., 2010)
supports the notion that ET pores are maintained open in
a long lasting manner. Cell-attached recordings, during
which ET has been applied inside the recording patch-
clamp pipette, have shown that ET induces large trans-
membrane unitary currents on granule cells in organo-
typic cerebellar slices (Lonchamp et al., 2010). The
corresponding unitary conductance of which has been
estimated around w270 pS. Such a conductance is larger
than that of most endogenous channels in neuron, except
the Ca2þ-dependent K channels (also termed big K) that
may reach 150 up to 250 pS. However, at variance of most
endogenous ionic channels, no voltage dependence has
been detected in ET-induced currents (Lonchamp et al.,
2010). The conductance of w270 pS induced by ET in
granule cell is compatible with that determined in bi-
layers membrane (w480 pS, Nestorovich et al., 2010;
w550 pS, Petit et al., 2001).
7.4. Role of cholesterol
Similar as for many cytolysins of bacterial origin, lipidic
environment in plasma membrane impacts the effects of ET.
Overall, the integrity of the plasma membrane is needed for
ET to exert its effects (Dorca-Arévalo et al., 2012; Nagahama
and Sakurai, 1992; Petit et al., 1997). Studies made using li-
posomes devoid of speciﬁc receptor have suggested that
membrane ﬂuidity plays an important role in the interaction
of ETwith liposomes, insertion in themembrane bilayer, and
assembly into complex process in the bilayer (Nagahama
et al., 2006; Petit et al., 2001). Reminiscent of data obtained
using renal cells (Chassinet al., 2007;Miyata et al., 2002; Petit
et al., 1997) the cholesterol sequestration by methyl-b-
cyclodextrin (mbCD) does not prevent ET binding onto target
neural cells as assessed by immuno-staining of ET on cere-
bellumslicesorculturedgranule cells (Lonchampetal., 2010).
Note, however, that a decrease in 35S-ET binding on rat syn-
aptosomes has been reported (Miyata et al., 2002). These
results are consistent with single-molecule tracking experi-
ments made on ET at the apical membrane of MDCK cells,
which have shown that the ET binding onto plasma mem-
branes does not require presence of cholesterol (Türkcanet al., 2012). Therefore, the cholesterol is dispensable for ET
binding to its receptor. This is not the case for the subsequent
steps. In the one hand, pre-incubation of renal cells with
mbCD prevents ET-oligomerization and ET-induced cyto-
toxicity (reviewed by Popoff, 2011a), and mbCD prevents ET-
oligomerization in synaptosomal membranes fractions
(Miyata et al., 2002). In the other hand, the oligomerization
process and the pore formation (see below) can occur in
artiﬁcial membrane in absence of cholesterol (Nagahama
et al., 2006; Petit et al., 2001). The contradiction between
these different insights is only apparent, and has recently
received an explanation. Indeed, the cholesterol plays an
essential role in the plasma membrane organization into
microdomains (i.e. DRM; detergent-resistant membrane)
that conﬁne lateralmembranediffusion of ETmonomeror ET
monomer bound to its receptor within small zones (of mean
areaw0.40 mm2 on MDCK cells (Türkcan et al., 2012)). This
conﬁned diffusion is likely to greatly enhance interactions
between ET monomers, thus facilitating their ensuing oligo-
merization into heptamers. Several types of cholesterol-rich
lipid rafts domains exist including planar lipid rafts and
caveolae, which are caveolin-dependent invaginations of the
plasma membrane (reviewed by Allen et al., 2007). ET hep-
tamers are detected in membrane fractions containing cav-
eolin (Miyata et al., 2002) and expression of caveolins greatly
potentiates ET-induced cytotoxicity inhumankidneycell line
ACHN (Fennessey et al., 2012). Thus caveolae allow conﬁne-
mentof ET into restrictedmembrane areas (i.e. DRM) thereby
favouring ET oligomerization and ensuing steps. To date, no
experiment suggests that the cholesterol is indispensable for
the membrane insertion of the ET pre-pore complex formed
onto the surface of target cells.
7.5. Causal linkage between formation of ET-pore and
cytotoxicity
Until now, there is no evidence that ET needs to enter
into target cells to induce cytotoxicity (reviewed by Bokori-
Brown et al., 2011; Popoff, 2011a, 2011b). Overall, it is
believed that ﬂux of ions and leakage of small molecules
through ET pores is the unique cause for ET-induced cell
death. In mpkCCDcl4 cells, ET induces fall in trans-
membrane resistance, rapid depletion of cellular ATP, and
stimulates the AMP-activated protein kinase, which is a
sensitive indicator of reduced cellular energy status. ET also
induces mitochondrial membranes permeabilization and
mitochondrial-nuclear translocation of apoptosis-inducing
factor. The cell death is caused by caspase-independent
necrosis characterized by a marked reduction in nucleus
size without DNA fragmentation; however this form of cell
death is not triggered by the abrupt increase in cytosolic
Ca2þ detected in these cells (Chassin et al., 2007). There is a
good correlation between the kinetics of ﬂuorescent dye
entry, supposedly via ET-pores, and the loss of MDCK cell
viability (Lewis et al., 2010; Petit et al., 2003, 2001). Site-
directed mutagenesis of amino acids within the putative
channel-forming domain resulted in changes of cytotox-
icity in MDCK cells (Knapp et al., 2009). Moreover, treat-
ments with mbCD prevent the loss of the plasma
membrane resistance and the rise in intracellular Ca2þ
concentration induced by ET in renal collecting duct
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in intracellular Ca2þ concentration and the induction of
glutamate efﬂux caused by ET in granule cells (Lonchamp
et al., 2010). Note, however, it remains unclear whether
the preventive effect of mbCD is due, as expected, to the
cholesterol sequestration from target cells membrane, or
direct blockade of ET pore, as recently reported for pores
formed by Bacillus anthracis lethal toxin and Staphylococcus
aureus a-haemolysin (Yannakopoulou et al., 2011).
Several data are not fully consistent with a strict causal
linkage between formation of ET pore and cellular effects,
especially for the early cellular manifestations of ET.
Indeed, ET can cause ATP depletion and oncosis in renal
collecting duct mpkCCDcl4 cells despite ET heptameriza-
tion is prevented by pre-treating cells with mbCD (Chassin
et al., 2007). Thus the cytotoxic effects of ET in mpkCCDcl4
cells appears dual and comprised of a pore-forming
cholesterol-dependent phase that occurs in DRMs, and an
ATP depletion induced oncosis that is almost completely
resistant to the removal of cholesterol. Pre-treatment of
cerebellar granule cells with mbCD prior to ET application
inside the recording pipette does not abolish appearance of
ET-induced transmembrane currents, but delays them and
reduce their amplitude (Lonchamp et al., 2010). Are these
current due to activation of endogenous membrane
conductance? Altogether, the emerging picture is that
some of the early cellular effects of ETmay not be caused by
formation of ET pore. This is in line with recent proposal
that certain pore-forming toxins act on host cells by
another way than forming pores, as recently reported for a
staphylococcal toxin (Jover et al., 2013).
8. ET as an excitatory neurotoxin
Several of the manifestations associated with C. per-
fringens type B and D enterotoxaemia (seizure, opisthoto-
nus, convulsion. see Table 1) indicate hyperexcitability of
the central nervous system, possibly resulting from an
imbalance between excitatory (i.e. glutamate) and inhibi-
tory (i.e. GABA) transmission. Thus, numerous studies have
investigated whether release of transmitters is increased
following ET administration, and may explain some of the
observed ET-induced manifestations.
The intraperitoneal administration of antagonists of the
ionotropic glutamate receptors (as MK801 to block NMDA
subtype glutamate receptors, or CNQX to antagonize AMPA
receptors) prior intravenous injection of ET in rat decreases
the number of pyramidal dark cells in the hippocampus
(Miyamoto et al., 1998) pinpointing these damage are due
to dramatic increase in ambient glutamate concentration in
neural tissue (i.e. dark cells manifest glutamate-induced
excitotoxicity). Accordingly, direct evidence for induction
of increased glutamatergic transmission has been obtained
using micro dialysis in the hippocampus in rat and mice
submitted to ET (Miyamoto et al., 2000, 1998). Moreover,
depletion in zinc ions – which has been shown contained
into glutamate-containing synaptic vesicles – in the mossy
layers of the hippocampal CA3 region has suggested that
the excess of glutamate was due to its vesicular release by
the nerve terminals (Miyamoto et al., 1998). Importantly,
these effects were demonstrated not due to brain ischemia.In cultured cerebellum slices, the frequency of excitatory
(glutamatergic) spontaneous responses in Purkinje cells is
strongly increased (Lonchamp et al., 2010). However, in
mice anesthetized with ketamine, intravenous injection of
ET-GFP does not produce the expected convulsive episodes
(Soler-Jover et al., 2007). This is does not necessarily in
contradiction with the observations commented just
above; indeed, ketamine, which is a well-known glutamate
NMDA receptor antagonist, may have minimized the
manifestations caused by ET-induced increase in excitatory
transmission. In granule cells cultures, ET induces gluta-
mate release as assessed using the Amplex red assay
(Lonchamp et al., 2010); but it remains unclear whether
glutamate release is due to stimulation of vesicular exocy-
tosis by the ET-induced rise in intracellular Ca2þ or rever-
sion of membrane glutamate transporter following ET-
induced membrane depolarization.
Several evidence support the view that the increase in
neurotransmitters release is not due to direct effect of ETon
nerve terminals. Indeed, in cerebellar slices, ET-induced
increase in glutamatergic synaptic events in Purkinje cell is
abolished by TTX (Tetrodotoxin, a blocker of Naþ channels)
well-known to prevent propagation of action-potentials
(Lonchamp et al., 2010). In hippocampus, ET-induced
glutamate efﬂux is greatly attenuated by riluzole
(Miyamoto et al., 2000), which is a blocker of TTX-sensitive
Naþ channels, too (Lamanauskas and Nistri, 2008). TTX has
been found also to abolish ET-induced contraction of ileum,
indicating contribution of propagated action potentials be-
tween the site of action of ET (enteric neurons) and acetyl-
choline secretion (Sakurai et al., 1989). Overall, the
emerging picture is that ET depolarizes the somatic mem-
brane of certain neurons, thereby initiating burst of action
potentials that propagate along the axons up to the nerve
terminals where they stimulate vesicular neurotransmitter
release. This proposal may explain the paradoxical situation
that ET is able to induce glutamate release (see previous
paragraph) despite it does not bind on nerve terminals
(Dorca-Arévalo et al., 2008; Lonchampet al., 2010) or induce
glutamate release from puriﬁed mouse and rat brain syn-
aptosomes (Dorca-Arévalo et al., 2008).
The stimulatory effect of ET on neurotransmitter release
is not restricted to the glutamatergic pathways. Indeed,
stimulation of dopamine, noradrenaline and adrenaline
release has been reported in mice and sheep (Buxton,
1978b; Nagahama and Sakurai, 1993; Worthington et al.,
1979). In ileum preparations, ET stimulates acetylcholine
release (Sakurai et al., 1989). However, it is not clear
whether these observations are due to direct action of ET
on non-glutamatergic neurons, or are secondary conse-
quences of the stimulation of glutamatergic system, which
is excitatory. Such a possibility is supported by the obser-
vation that in the cerebellar network, ET induces an in-
crease in GABA transmission that can be completely
prevented by inhibiting glutamatergic transmission
(Lonchamp et al., 2010). Overall, by acting on glutamatergic
neurons, ET induces increase in glutamate levels, which in
turn triggers ﬁring of the whole nervous system, leading to
many indirect manifestations. For example, the ET-induced
rise in circulating catecholamine (indicating over-
stimulation of sympathetic system) activates adenylate
L. Wioland et al. / Toxicon 75 (2013) 122–135 133cyclase pathways resulting in plasma cyclic-adenosine-30,
50 monophosphate (cAMP) rise after ET injection (Buxton,
1978b; Worthington et al., 1979), an effect that may
explain hyperglycaemia (Bullen and Scarisbrick, 1957;
Gardner, 1973a).
9. Conclusion
ET has the fundamental structure of a pore-forming
toxin, and accordingly it is expected to interact with
many various cell types. Indeed, pore-forming toxins
recognize ubiquitous membrane components as re-
ceptors, such as cholesterol, glycosylated proteins and
therefore they can indiscriminately damage membranes
from different cells. Consistent with such a notion, the
action of ET is not restricted to the neural cells: it acts on
epithelial cells in intestine and kidney, and vascular
endothelial cells. Therefore, the neurotoxin properties of
ET may result from the fact that same molecules and
signalling cascade participates in the biology of all ET
target cells. However, despite in the pathophysiological
condition the actual concentration of ET in brain is likely
far lower than that in the periphery; the prominent effects
of ET are due to the nervous system attack. Does this mean
that ET is more a neurotoxin than a cytolysin? Perhaps!
One should consider that ET is singular among the other
bacterial toxins because its ability to interact with
vascular endothelial cells makes it able to enter the brain
tissue by crossing the blood–brain barrier. Since the ner-
vous system is the central coordinator for metazoan, any
attack on it produces severe symptoms and manifesta-
tions. Acting on neurons and, possibly the oligodendro-
cytes, ampliﬁes the highly potent systemic action of ET.
This may explain why ET lethal activity is 100-fold higher
than that of other structurally related pore-forming
toxins. Prominence of the neural effects (as in the acute
form of the disease) should not distract our interest from
more discrete manifestations that may allow identifying
new target cells for ET, and may help to anticipate long-
term effects of sub-lethal doses of ET.
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